Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GH NYSE:HIMS NASDAQ:NTRA NASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$67.51-3.8%$61.62$20.14▼$70.33$8.75B1.532.24 million shs2.55 million shsHIMSHims & Hers Health$49.40-3.8%$51.07$18.33▼$72.98$11.61B2.2530.76 million shs29.58 million shsNTRANatera$186.88-0.9%$169.37$117.27▼$196.63$25.88B1.741.21 million shs782,467 shsRDNTRadNet$80.16+2.2%$73.50$45.00▼$93.65$6.03B1.59542,601 shs809,367 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health+7.24%+13.72%+18.68%+51.78%+228.34%HIMSHims & Hers Health+3.27%-6.29%-10.98%+2.95%+132.05%NTRANatera+3.80%+8.29%+4.14%+34.79%+54.08%RDNTRadNet+1.96%+9.37%+2.62%+37.28%+15.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$67.51-3.8%$61.62$20.14▼$70.33$8.75B1.532.24 million shs2.55 million shsHIMSHims & Hers Health$49.40-3.8%$51.07$18.33▼$72.98$11.61B2.2530.76 million shs29.58 million shsNTRANatera$186.88-0.9%$169.37$117.27▼$196.63$25.88B1.741.21 million shs782,467 shsRDNTRadNet$80.16+2.2%$73.50$45.00▼$93.65$6.03B1.59542,601 shs809,367 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health+7.24%+13.72%+18.68%+51.78%+228.34%HIMSHims & Hers Health+3.27%-6.29%-10.98%+2.95%+132.05%NTRANatera+3.80%+8.29%+4.14%+34.79%+54.08%RDNTRadNet+1.96%+9.37%+2.62%+37.28%+15.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHGuardant Health 2.92Moderate Buy$65.86-2.45% DownsideHIMSHims & Hers Health 1.93Reduce$38.92-21.22% DownsideNTRANatera 2.89Moderate Buy$196.815.31% UpsideRDNTRadNet 3.13Buy$76.80-4.19% DownsideCurrent Analyst Ratings BreakdownLatest NTRA, HIMS, GH, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025HIMSHims & Hers HealthKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight10/14/2025HIMSHims & Hers HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/14/2025NTRANateraCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.0010/14/2025RDNTRadNetZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025GHGuardant HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NTRANateraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RDNTRadNetWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/7/2025GHGuardant HealthEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$60.00 ➝ $68.0010/2/2025GHGuardant HealthBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$60.00 ➝ $70.009/27/2025GHGuardant HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025HIMSHims & Hers HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHGuardant Health$739.02M11.39N/AN/A($1.13) per share-59.74HIMSHims & Hers Health$1.48B7.56$0.34 per share145.84$2.16 per share22.87NTRANatera$1.70B15.12N/AN/A$9.05 per share20.65RDNTRadNet$1.83B3.37$3.56 per share22.52$15.31 per share5.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHGuardant Health-$436.37M-$3.35N/AN/AN/A-49.93%N/A-28.95%10/29/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.8061.7595.003.509.63%26.26%13.06%11/3/2025 (Estimated)NTRANatera-$190.43M-$1.91N/AN/AN/A-12.89%-22.22%-15.03%11/11/2025 (Estimated)RDNTRadNet$2.79M-$0.20N/A151.25N/A-0.78%2.41%0.82%11/10/2025 (Estimated)Latest NTRA, HIMS, GH, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025NTRANatera-$0.40N/AN/AN/A$514.55 millionN/A11/10/2025Q3 2025RDNTRadNet$0.23N/AN/AN/A$494.19 millionN/A11/3/2025Q3 2025HIMSHims & Hers Health$0.09N/AN/AN/A$578.99 millionN/A10/29/2025Q3 2025GHGuardant Health-$0.48N/AN/AN/A$235.72 millionN/A8/10/2025Q2 2025RDNTRadNet$0.17$0.31+$0.14$0.43$488.06 million$498.23 million8/7/2025Q2 2025NTRANatera-$0.60-$0.74-$0.14-$0.74$476.84 million$546.60 million8/4/2025Q2 2025HIMSHims & Hers Health$0.18$0.17-$0.01$0.17$550.06 million$544.83 million7/30/2025Q2 2025GHGuardant Health-$0.52-$0.44+$0.08-$0.80$211.19 million$232.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHGuardant HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHGuardant HealthN/A3.713.35HIMSHims & Hers Health1.724.984.46NTRANateraN/A3.723.58RDNTRadNet0.912.002.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHGuardant Health92.60%HIMSHims & Hers Health63.52%NTRANatera99.90%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipGHGuardant Health6.10%HIMSHims & Hers Health17.71%NTRANatera5.63%RDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHGuardant Health2,021124.71 million117.10 millionNot OptionableHIMSHims & Hers Health1,637226.02 million185.99 millionOptionableNTRANatera4,434137.25 million129.52 millionOptionableRDNTRadNet11,02176.92 million72.61 millionOptionableNTRA, HIMS, GH, and RDNT HeadlinesRecent News About These CompaniesRadNet to Host Investor Day on November 11, 2025October 21 at 6:00 AM | globenewswire.comRadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference CallOctober 20 at 7:47 AM | markets.businessinsider.comPraxis Investment Management Inc. Purchases Shares of 3,960 RadNet, Inc. $RDNTOctober 20 at 3:14 AM | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) Receives Average Recommendation of "Buy" from BrokeragesOctober 18 at 4:28 AM | marketbeat.comDesert Oasis Healthcare and RadNet Partner to Advance Early Breast Cancer DetectionOctober 18 at 3:36 AM | pharmiweb.comPWCM Investment Management LLC Buys 14,255 Shares of RadNet, Inc. $RDNTOctober 17, 2025 | marketbeat.comTruist Financial Corp Makes New Investment in RadNet, Inc. $RDNTOctober 17, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Raised to Strong-Buy at Zacks ResearchOctober 16, 2025 | marketbeat.comRadNet, Inc. $RDNT Shares Purchased by Allspring Global Investments Holdings LLCOctober 14, 2025 | marketbeat.comRadNet's (RDNT) "Sell (D)" Rating Reiterated at Weiss RatingsOctober 10, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Has $696,000 Stock Position in RadNet, Inc. $RDNTOctober 4, 2025 | marketbeat.comState of Alaska Department of Revenue Grows Stock Holdings in RadNet, Inc. $RDNTOctober 3, 2025 | marketbeat.comRadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025September 26, 2025 | globenewswire.comSteigerwald Gordon & Koch Inc. Sells 4,195 Shares of RadNet, Inc. $RDNTSeptember 23, 2025 | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) Receives Consensus Rating of "Buy" from AnalystsSeptember 23, 2025 | marketbeat.comInvesting in RadNet (NASDAQ:RDNT) five years ago would have delivered you a 410% gainSeptember 22, 2025 | finance.yahoo.comFulton Bank N.A. Makes New Investment in RadNet, Inc. $RDNTSeptember 21, 2025 | marketbeat.comTesting & Diagnostics Services Q2 Earnings: Guardant Health (NASDAQ:GH) is the Best in the BizSeptember 19, 2025 | msn.comCornelis Wesdorp Sells 500 Shares of RadNet (NASDAQ:RDNT) StockSeptember 16, 2025 | insidertrades.comNorman Hames Sells 10,000 Shares of RadNet (NASDAQ:RDNT) StockSeptember 13, 2025 | insidertrades.comInsider Selling: RadNet (NASDAQ:RDNT) CEO Sells 500 Shares of StockSeptember 11, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Top 3 Dividend Achievers for October: High Yields, Growth AheadBy Thomas Hughes | October 1, 2025NTRA, HIMS, GH, and RDNT Company DescriptionsGuardant Health NASDAQ:GH$67.51 -2.69 (-3.83%) Closing price 04:00 PM EasternExtended Trading$67.50 -0.01 (-0.01%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Hims & Hers Health NYSE:HIMS$49.40 -1.96 (-3.82%) Closing price 03:59 PM EasternExtended Trading$49.44 +0.05 (+0.09%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Natera NASDAQ:NTRA$186.88 -1.72 (-0.91%) Closing price 04:00 PM EasternExtended Trading$188.19 +1.31 (+0.70%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.RadNet NASDAQ:RDNT$80.16 +1.72 (+2.19%) Closing price 04:00 PM EasternExtended Trading$82.18 +2.02 (+2.52%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
